Robot guided stepping improves walking
- Trial ID
- NCT05218187
- Official Title
- Robotic Gait Rehabilitation in Parkinson's Disease
- Goal
- Robot guided stepping improves walking
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Indiana University
- Study Type
- INTERVENTIONAL
- Enrollment
- 30 participants
- Conditions
- Parkinson Disease, Gait Disorder, Sensorimotor
- Interventions
- G-EO End-Effector Gait Trainer, Conventional Physical Therapy Treatment
Plain-Language Summary
The goal is to improve walking and balance by retraining stepping patterns and reducing the gait problems that make daily mobility harder for people with Parkinson's. It uses a G-EO end-effector robotic gait trainer that moves and guides the feet to give high-intensity, repetitive stepping practice, compared with conventional physical therapy; the robot’s programmable support aims to improve step symmetry, endurance, and confidence, and the program is meant to be used alongside stable Parkinson's medications and deep brain stimulation settings. Adults 18 and older with Parkinson's at Hoehn and Yahr stages 1 to 3 who need functional rehabilitation, have an MMSE above 24, physician clearance, stable meds for 3 months and stable DBS for a year can be eligible, while people with severe dyskinesia or on-off fluctuations, unstable meds, recent similar therapy, device height/weight limits, or other walking-limiting conditions are not.
Locations
- IU Health Neurorehabilitation and Robotics, Indianapolis, Indiana, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying G-EO End-Effector Gait Trainer. The goal is to improve walking and balance by retraining stepping patterns and reducing the gait problems that make daily mobility harder for people with Parkinson's. It uses a G-EO end-effector robotic gait trainer that moves and guides the feet to give high-intensity, repetitive stepping practice, compared with conventional physical therapy; the robot’s programmable support aims to improve step symmetry, endurance, and confidence, and the program is meant to be used alongside stable Parkinson's medications and deep brain stimulation settings. Adults 18 and older with Parkinson's at Hoehn and Yahr stages 1 to 3 who need functional rehabilitation, have an MMSE above 24, physician clearance, stable meds for 3 months and stable DBS for a year can be eligible, while people with severe dyskinesia or on-off fluctuations, unstable meds, recent similar therapy, device height/weight limits, or other walking-limiting conditions are not.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years and 11 months.